Sign in
CLNNW Stock Price, Chart, Stats & News
Clene Inc.
Save
2.16M
Market cap
–
Current P/E
–
Forward P/E
CLNNW chart
1M
3M
1Y
5Y
Loading chart...
Fundamentals
Gross margin | 78.50% |
Operating margin | -11541.50% |
Pretax margin | -13086.50% |
Net margin | -13086.50% |
Effective tax rate | – |
ROA | -144.35% |
ROE | 240.83% |
D/E | -1.23x |
Interest coverage ratio | -8.61x |
CLNNW valuation
P/E | – |
P/S | 235.50x |
P/B | -2.64x |
P/CF | -2.50x |
P/FCF | -2.53x |
P/OCF | -2.50x |
PEG | -0.06x |
EV multiple | -1.42x |
About
Clene Inc. is a clinical-stage pharmaceutical firm dedicated to the discovery, development, and market introduction of innovative therapeutic agents derived from clean-surfaced nanotechnology (CSN). The company's primary drug candidate, CNM-Au8, is currently undergoing extensive clinical evaluation for various neurological conditions. For Amyotrophic Lateral Sclerosis (ALS), it's being tested in a pivotal Phase 2/3 registrational clinical trial, building on a previously completed Phase 2 "proof-of-concept" study in patients with early symptomatic ALS.
Similar securities
Based on sector and market capitalization
Report issue